A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years

被引:176
|
作者
Sifuentes, Monica
Doroshow, Robin
Hoft, Richard
Mason, Greg
Walot, Irwin
Diament, Michael
Okazaki, Susan
Huff, Kenneth
Cox, Gerald F.
Swiedler, Stuart J.
Kakkis, Emil D.
机构
[1] BioMarin Pharmaceut Inc, Novato, CA 94949 USA
[2] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90502 USA
[3] Harbor UCLA Med Ctr, Dept Ophthalmol, Torrance, CA 90502 USA
[4] Harbor UCLA Med Ctr, Dept Med, Torrance, CA 90502 USA
[5] Harbor UCLA Med Ctr, Dept Radiol, Torrance, CA 90502 USA
[6] Harbor UCLA Med Ctr, Dept Phys Therapy, Torrance, CA 90502 USA
[7] Genzyme Corp, Clin Res, Cambridge, MA 02142 USA
关键词
cardiac function; efficacy; enzyme replacement therapy; Hurler-Scheie; joint stiffness; laronidase; mucopolysaccharidosis I; Scheie;
D O I
10.1016/j.ymgme.2006.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant human alpha-L-iduronidase (Aldurazyme (R), laronidase) was approved as an enzyme replacement therapy for patients with the lysosomal storage disorder, mucopolysaccharidosis I (NIPS I). In order to assess the long-term safety and efficacy of laronidase therapy, 5 of 10 patients in the original laronidase Phase 1/2 clinical trial were re-evaluated after 6 years of treatment. Lysosomal storage was further improved at 6 years (urinary glycosaminoglycans (GAG) excretion decreased 76%; mean liver size at 1.84% of body weight). Shoulder maximum range of motion was maintained or further increased and reached a mean 33.2 (R) and 25.0 (L) degrees gained in flex-ion and 34.0 (R) and 27.3 (L) degrees gained in extension. Sleep apnea was decreased in four of five patients and the airway size index improved. Cardiac disease evaluations showed no progression to heart failure or cor pulmonale but pre-existing significant valve disease did progress in some patients. Substantial growth was observed for the pre-pubertal patients, with a gain of 33 cm (27%) in height and a gain of 31 kg in weight (105%). In general, the evaluated patients reported an improved ability to perform normal activities of daily living. Overall these data represent the first evidence that laronidase can stabilize or reverse many aspects of MPS I disease during long-term therapy and that early treatment prior to the development of substantial cardiac and skeletal disease may lead to better outcomes. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 50 条
  • [11] Aldurazyme (laronidase) enzyme replacement therapy for MPS I: 72-week extension data.
    Clarke, LA
    Wraith, JE
    Beck, M
    Kolodny, EH
    Pastores, GM
    Muenzer, J
    MOLECULAR GENETICS AND METABOLISM, 2004, 81 (03) : 169 - 169
  • [12] FIVE YEARS' FOLLOW-UP OF ENZYME REPLACEMENT THERAPY IN MUCOPOLYSACCHARIDOSIS I (HURLER SYNDROME): A CASE REPORT
    Arion, A.
    Kauffmann, D.
    Brouard, J.
    Ribault, V.
    Guffon-Fouilhoux, N.
    CLINICAL THERAPEUTICS, 2008, 30 : S120 - S121
  • [13] Aldurazyme® (laronidase) enzyme replacement therapy in MPS I:: Preliminary safety data in children less than 5 years of age.
    Guffon, N
    Wraith, JE
    Braakman, T
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 623 - 623
  • [14] Clinical and laboratorial alterations in 3 MPS I patients receiving enzyme replacement therapy (ERT) with laronidase: A 22 months experience
    Kyosen, S. O.
    Micheletti, C.
    Braghiroli, P. S.
    Toma, L.
    Secches, T. A. V. A.
    Mendes, C. S. C.
    Rand, M. H.
    Nader, H. B.
    D'Almeida, V
    Martins, A. M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 152 - 152
  • [15] Survival, cardiac, and pulmonary outcomes in individuals with attenuated MPS I receiving laronidase enzyme replacement therapy: Data from the MPS I Registry
    Ghosh, Arunabha
    Giuglianib, Roberto
    Clarkec, Lorne A.
    Muschold, Nicole M.
    Jonesa, Simon A.
    Batistae, Julie L.
    Florese, Ana Lorena
    Wilsonf, Kathryn
    Muenzerg, Joseph
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [16] Aldurazyme® (laronidase) enzyme replacement therapy for mucopolysaccharidosis I:: A dose optimization study
    Cox, G. E.
    Giugliani, R.
    Martins, A. M.
    Valadares, E. R.
    Clarke, J. T. R.
    Goes, J. E. C.
    Worden, M. A.
    Sidman, M.
    Kakkis, E. D.
    CLINICAL THERAPEUTICS, 2007, 29 : S125 - S126
  • [17] Experience with enzyme replacement therapy in 6 MPS VI patients
    Valayannopoulos, V.
    Chabli, A.
    Lemoine, M.
    Odent, T.
    Goldenberg, A.
    Barbier, V
    Caillaud, C.
    Lemerrer, M.
    de Lonlay, P.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 110 - 110
  • [18] Laronidase (Aldurazyme®):: enzyme replacement therapy for mucopolysaccharidosis type I
    Pastores, Gregory M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) : 1003 - 1009
  • [19] Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
    Jameson, Elisabeth
    Jones, Simon
    Wraith, James E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (11):
  • [20] A follow-up observation of enzyme replacement therapy in Pompe Disease
    Dubrovsky, A.
    Corderi, J. C.
    Amartino, H.
    Calle, A.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 800 - 801